Literature DB >> 28844314

Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit?

Andrew Davenport1, Mohammed Faisal Sheikh2, Edmund Lamb3, Banwari Agarwal4, Rajiv Jalan2.   

Abstract

Renal dysfunction occurs in 25% to 50% of patients with cirrhosis admitted to the hospital with an acute episode of hepatic decompensation and may be due to underlying chronic kidney disease, an acute deterioration, or both. An acute deterioration in renal function in cirrhotic patients is now collectively referred to as acute kidney injury (AKI), which has been subclassified into different grades of severity that identify prognostic groups. Acute-on-chronic liver failure is characterized by acute hepatic and/or extrahepatic organ failure driven by a dysregulated immune response and systemic inflammatory response. AKI is also one of the defining features of ACLF and a major component in grading the severity of acute-on-chronic liver failure. As such, the pattern of AKI now observed in patients admitted to the hospital with acutely decompensated liver disease is likely to be one of inflammatory kidney injury including acute tubular injury (referred in this review as non-hepatorenal syndrome [HRS]-AKI) rather than HRS. As the management and supportive treatment of non-HRS-AKI potentially differ from those of HRS, then from the nephrology perspective, it is important to distinguish between non-HRS-AKI and HRS-AKI when reviewing patients with acute-on-chronic liver failure and AKI, so that appropriate and early management can be instituted.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACLF; acute kidney injury; cirrhosis; hepatorenal syndrome

Mesh:

Substances:

Year:  2017        PMID: 28844314     DOI: 10.1016/j.kint.2017.04.048

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  22 in total

1.  Analysis of the high incidence of acute kidney injury associated with acute-on-chronic liver failure.

Authors:  Nan Chen; Xiaohong Chen; Xiaoqiang Ding; Jie Teng
Journal:  Hepatol Int       Date:  2018-04-28       Impact factor: 6.047

2.  Incidence and risk factors of contrast-induced nephropathy after transcatheter arterial chemoembolization in hepatocellular carcinoma.

Authors:  Mari Aoe; Takafumi Kanemitsu; Takamasa Ohki; Satoru Kishi; Yoshiyasu Ogura; Yuto Takenaka; Toyohiro Hashiba; Hiroko Ambe; Emi Furukawa; Yu Kurata; Masahiro Ichikawa; Ken Ohara; Tomoko Honda; Satoshi Furuse; Katsunori Saito; Nobuo Toda; Naobumi Mise
Journal:  Clin Exp Nephrol       Date:  2019-06-10       Impact factor: 2.801

Review 3.  Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.

Authors:  Juan Carlos Q Velez; George Therapondos; Luis A Juncos
Journal:  Nat Rev Nephrol       Date:  2019-11-13       Impact factor: 28.314

4.  Bile Acids Are Important Contributors to AKI Associated with Liver Disease: PRO.

Authors:  Peter Fickert; Alexander R Rosenkranz
Journal:  Kidney360       Date:  2021-05-03

5.  Midodrine Improves the Tolerability of Diuretics in Patients with Acute-on-Chronic Liver Failure-A Pilot Study.

Authors:  Anand V Kulkarni; Pramod Kumar; Mithun Sharma; Sowmya T Ravikumar; Harshvardhan Tevethia; Samragni Vasireddy; Rajesh Gupta; Duvvuru N Reddy; Padaki N Rao
Journal:  J Clin Exp Hepatol       Date:  2020-12-17

Review 6.  Management of acute renal replacement therapy in critically ill cirrhotic patients.

Authors:  Jimena Del Risco-Zevallos; Alicia Molina Andújar; Gastón Piñeiro; Enric Reverter; Néstor David Toapanta; Miquel Sanz; Miquel Blasco; Javier Fernández; Esteban Poch
Journal:  Clin Kidney J       Date:  2022-01-28

Review 7.  Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis.

Authors:  Frederik Nevens; Paulo Lisboa Bittencourt; Minneke J Coenraad; Huiguo Ding; Ming-Chih Hou; Pierre-François Laterre; Manuel Mendizabal; Nayeli Xochiquetzal Ortiz-Olvera; Julio D Vorobioff; Wenhong Zhang; Paolo Angeli
Journal:  Dig Dis Sci       Date:  2019-01-25       Impact factor: 3.199

8.  Disruption of Renal Arginine Metabolism Promotes Kidney Injury in Hepatorenal Syndrome in Mice.

Authors:  Zoltan V Varga; Katalin Erdelyi; Janos Paloczi; Resat Cinar; Zsuzsanna K Zsengeller; Tony Jourdan; Csaba Matyas; Balazs Tamas Nemeth; Adrien Guillot; Xiaogang Xiang; Adam Mehal; György Haskó; Isaac E Stillman; Seymour Rosen; Bin Gao; George Kunos; Pal Pacher
Journal:  Hepatology       Date:  2018-10       Impact factor: 17.425

Review 9.  INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease.

Authors:  Anil Arora; Ashish Kumar; Narayan Prasad; Ajay Duseja; Subrat K Acharya; Sanjay K Agarwal; Rakesh Aggarwal; Anil C Anand; Anil K Bhalla; Narendra S Choudhary; Yogesh K Chawla; Radha K Dhiman; Vinod K Dixit; Natarajan Gopalakrishnan; Ashwani Gupta; Umapati N Hegde; Sanjiv Jasuja; Vivek Jha; Vijay Kher; Ajay Kumar; Kaushal Madan; Rakhi Maiwall; Rajendra P Mathur; Suman L Nayak; Gaurav Pandey; Rajendra Pandey; Pankaj Puri; Ramesh R Rai; Sree B Raju; Devinder S Rana; Padaki N Rao; Manish Rathi; Vivek A Saraswat; Sanjiv Saxena; Praveen Sharma; Shivaram P Singh; Ashwani K Singal; Arvinder S Soin; Sunil Taneja; Santosh Varughese
Journal:  J Clin Exp Hepatol       Date:  2020-10-09

10.  Fiber scaffold bioartificial liver therapy relieves acute liver failure and extrahepatic organ injury in pigs.

Authors:  Jun Weng; Xu Han; Fanhong Zeng; Yue Zhang; Lei Feng; Lei Cai; Kangyan Liang; Shusong Liu; Shao Li; Gongbo Fu; Min Zeng; Yi Gao
Journal:  Theranostics       Date:  2021-06-11       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.